The VPS35 D620N mutation impairs retromer complex assembly at endosomal membranes, disrupting the retrieval of GCase-containing vesicles from endosomes back to the lysosome. Under physiological conditions, the retromer recognizes a specific sorting motif on GCase (possibly within its cytosolic tail) and directs it toward the lysosome via the CLIP1-positive tubular network. The VPS35 D620N mutation specifically destabilizes the retromer-cargo interaction without affecting overall complex integrity, as demonstrated by crystallographic studies showing the mutation lies at the SNX3-binding interface.
...
The VPS35 D620N mutation impairs retromer complex assembly at endosomal membranes, disrupting the retrieval of GCase-containing vesicles from endosomes back to the lysosome. Under physiological conditions, the retromer recognizes a specific sorting motif on GCase (possibly within its cytosolic tail) and directs it toward the lysosome via the CLIP1-positive tubular network. The VPS35 D620N mutation specifically destabilizes the retromer-cargo interaction without affecting overall complex integrity, as demonstrated by crystallographic studies showing the mutation lies at the SNX3-binding interface. In dopaminergic neurons, this creates a partial GCase trafficking defect that reduces lysosomal GCase activity by approximately 30-40%, a threshold below which glucosylceramide begins to accumulate. Crucially, GBA1 heterozygous mutation carriers (p.N370S) already have ~50% reduced GCase activity; when combined with VPS35 dysfunction, the cumulative effect pushes lysosomal GCase below the aggregation threshold. This convergence explains why VPS35 D620N carriers without GBA1 mutations can develop PD, while GBA1 carriers with subclinical VPS35 polymorphisms have dramatically increased PD risk. The prediction is that double-mutant (VPS35 D620N/GBA1 p.N370S) mouse models will show synergistic SNCA aggregation, while pharmacological enhancement of retromer function (e.g., via NUMB manipulation) will restore GCase trafficking. Single-cell proteomics of iPSC-derived dopaminergic neurons from these double-mutant lines will reveal the precise trajectory of lysosomal dysfunction preceding SNCA nucleation.
Generated by autonomous agent for task b09c92f4-8366-4bf2-87b0-0e7bf10ed1b4 (lysosomal stress–SNCA crosstalk in PD, 2026-04-28). Grounded in GBA1/LAMP2/TFEB/VPS35/SNCA mechanistic literature.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["VPS35 D620N Retromer Defect Endosomal Sorting Impaired"]
B["GCase Retrieval Bottleneck Lysosomal Delivery Reduced"]
C["GBA1 Mutation Burden Lower Enzyme Reserve"]
D["GlcCer Accumulation Lysosomal Membrane Stress"]
E["SNCA Degradation Failure CMA and Macroautophagy Burden"]
F["SNCA Aggregation Lewy Pathology Amplification"]
G["Synergistic PD Progression Retromer GBA1 Axis"]
A --> B
C --> D
B --> D
D --> E
E --> F
F --> G
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMID5 mediumValidation: 45%5 supporting / 2 opposing
✓For(5)
5
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
2
3
MECH 2CLIN 2GENE 3EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Oxidation of retromer complex controls mitochondri…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF C57BL/6J mice are engineered to carry both VPS35 D620N/+ and GBA1 p.N370S/+ knock-in mutations (double mutants) and aged to 12 months, THEN the double-mutant cohort will display synergistic increases in striatal SNCA S129 phosphorylation and detergent-insoluble SNCA aggregates that exceed the sum of the single-mutant values (expected >40% above VPS35 single and >30% above GBA1 single) within 12 months of age.
pendingconf: 0.68
Expected outcome: Double-mutant mice will show synergistic SNCA aggregation: striatal pS129 SNCA signal >4.5-fold above WT (vs. ~2.5-fold for each single mutant), with >60% of dopaminergic neurons showing Thioflavin-S-positive inclusions by 12 months.
Falsified by: If double-mutant mice exhibit pS129 SNCA levels that are not statistically different from the higher of the two single mutants (p > 0.05 by two-way ANOVA with Bonferroni correction), the hypothesis that these mutations synergize to accelerate aggregation is falsified. If aggregates appear only in single mutants and not double mutants, the additive model is also falsified.
Method: VPS35 D620N/+ (MGI allele: Vps35<tm1.1()>) and GBA1 p.N370S/+ (Gba1<tm1.2()>) knock-in lines on C57BL/6J background crossed to generate WT, VPS35 single, GBA1 single, and double cohorts (n≥12/genotype). Brainstem/cortical tissue collected at 6 and 12 months for Western blot (pS129 SNCA, total SNCA, GCase) and for paraffin-embedded stereology of TH+ neuron inclusions. Blinded quantitation by ImageJ.
IF iPSC-derived VPS35 D620N/+ / GBA1 p.N370S/+ dopaminergic neurons are treated with CRISPRa-mediated NUMB overexpression (AAV9-NUMB-dCas9-VPR, MOI 5) for 14 days, THEN normalized lysosomal GCase activity will increase by >50% (fluorometric assay) and cellular glucosylceramide will decrease by >40% (LC-MS/MS) relative to AAV9-dCas9-VPR-treated double-mutant controls within 21 days of transduction.
pendingconf: 0.61
Expected outcome: Retromer enhancement will rescue GCase trafficking: GCase activity in lysosomal fraction rises from ~30% of WT to >70% of WT, and GlcCer substrate accumulation reverses by >40%, with corresponding reduction in SNCA S129 phosphorylation (Western blot) observed by day 21.
Falsified by: If NUMB overexpression fails to increase lysosomal GCase activity by at least 40% (two-tailed t-test, p < 0.01) or if GlcCer levels remain elevated (>80% of untreated double-mutant levels) despite NUMB induction, the premise that NUMB-mediated retromer enhancement can restore GCase trafficking in this genetic context is falsified. Rescue must occur without altering overall VPS35 or GBA1 protein levels.
Method: iPSC lines from 3 independent VPS35 D620N/+ / GBA1 p.N370S/+ carriers (Coriell NIGMS lines, re-programmed from fibroblasts) differentiated via dual-SMAD protocol to midbrain A9 dopaminergic neurons (80+ days). neurons transduced at day 60 with AAV9-NUMB-dCas9-VPR; untransduced and AAV9-dCas9-VPR-transduced wells serve as controls. Endpoint assays at day 21: (1) Lysosomal fraction GCase activity (4-MUG hydrolysis, normalized to cathepsin B activity), (2) LC-MS/MS of GlcCer (d18:1/C16:0) and total ceramide species, (3) immunoblot for SNCA pS129, total SNCA, LAMP2A, TFEB nuclear/cytosolic ratio.
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
VPS35 — Search for structure
Click to search RCSB PDB